: iStockAnalyst.com Symbols Feed

FDA Calendar Extreme Trades: 85 Single Digit Stocks

Tue, 13 Oct 2009 16:29:25 GMT

The BioMedReports.com FDA Calendar database includes over 400 entries of (1) pending new drug, biological agent, or medical device new product decisions at the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, and sBLA filings); (2) pending new submissions to the FDA; (3) pending complete response letter (CRL) re-submissions to the FDA; and (4) pending clinical trial results.[More...]

Dendreon (DNDN) Rises As New Board Members Are Appointed

Mon, 12 Oct 2009 18:00:22 GMT

DNDN: Shares of Dendreon (DNDN) traded higher by nearly eight percent during early trading on Monday after it became apparent that the company had recently appointed two new members to its Board of Directors, one being the Chief Executive of Genentech, Ian Clark and the other being Pedro Granadillo, a one time executive for Eli Lilly & Co.[More...]

The Next Big Thing In Health Care: How To Profit From Immunotherapy & Regenerative Medicine

Wed, 07 Oct 2009 19:22:50 GMT

The procedure has been called "one of the most barbaric mistakes ever perpetrated by mainstream medicine." Back when medicine was highly primitive, the process involved shoving an ice pick-like instrument between the upper eyelid and the eye in hopes of severing certain nerves of the frontal lobe.[More...]

SurModics, Inc. (SRDX) Signs Agreement With Genentech and Roche

Wed, 07 Oct 2009 16:22:36 GMT

SurModics, Inc. announced yesterday that it has signed an exclusive agreement with the Roche Group and Genentech for the licensing of its proprietary drug delivery system. This agreement will also establish a development process whereby a new, sustained-delivery formulation for the highly successful Lucentis® (ranibizumab) injection will be commercialized and brought to market using SurModics’ technology, logistics and expertise.[More...]

BioMed News Bytes: Dendreon, Chelsea, Cytori, Cephalon, OraSure, Genzyme, Lixte

Thu, 24 Sep 2009 23:01:08 GMT

On 4/28/09, Dendreon (NASDAQ: DNDN) announced that its experimental cancer vaccine Provenge extended the life of patients with advanced prostate cancer by a median of 4.1 months, which is one month longer than the only other treatment option, Taxotere.[More...]

BioMed News Bytes: BSD Medical, Provectus, Incyte, OncoMethylome

Tue, 22 Sep 2009 16:37:17 GMT

On 9/21/09, Provectus Pharma (OTC: PVCT.OB) ($0.96, +1%, above-average volume on 21-Sep) announced that it completed the treatment portion, including all protocol-allowed retreatments of all patients, of its Phase 2 clinical trial of PV-10 for metastatic melanoma. The study involved treatment of 80 subjects with Stage III or Stage IV metastatic melanoma. The primary objective of the Phase 2 study is to investigate the effectiveness of intralesional (IL) PV-10[More...]

Pressure BioSciences (NASDAQ: PBIO): A New Paradigm For Sample Processing

Mon, 21 Sep 2009 03:49:21 GMT

Pressure BioSciences (NASDAQ: PBIO) is a life science research tools company that is commercializing and developing its innovative core technology platform known as pressure cycling technology (PCT). PCT uses cycles of hydrostatic (water-based) pressure between ambient and ultra-high levels (up to 45,000 PSI) at controlled temperatures to rapidly and repeatedly control interactions at the molecular level.[More...]

Emerging Market Or Pharma

Tue, 25 Aug 2009 18:52:22 GMT

The shape of the global market for pharmaceuticals is undergoing a rapid change. As recently as 2006, more than half of the market growth was in the United States. This data comes from IMS Health, a consultancy that is a leading provider of pharmaceutical trends.[More...]

Spotlight On: Biotech

Sun, 09 Aug 2009 19:06:17 GMT

Spotlight On: Biotech The U.S. biotechnology industry includes about 1,000 companies, of all sizes, with combined annual revenues close to $50 billion. Large companies include Amgen, Biogen Idec, Genetech, Genzyme, Life Technologies and Monsanto. Because so many drugs are now developed using biotechnology, the biotech and pharmaceutical industries overlap. Demand for biotechnology products and services is driven primarily by the willingness of insurers to pay for new medical treatments. With the pending introduction of Obamacare, new uncertainties are introduced to this industry. Biotech products and treatments tend to be expensive and the drive to reduce costs through rationing will no doubt effect this industry. The profitability of individual companies depends on the discovery and effective marketing of new products. Because the market for potential[More...]

Catch These Stocks And You'll Never Have To Work Again

Wed, 29 Jul 2009 15:52:16 GMT

There's no fever like gold fever... unless you're in a biotech bull market. Since 1980, the Datastream Biotech Index has enjoyed four separate triple-digit rallies... including a 646% moonshot in the late 1990s and a 421% blast in the mid-1980s. In the early 1990s, the index rose 1,347% in less than four years. We crunched the numbers on biotech bull markets and found the average gain in a biotech bull market is 565% over 2.6 years. There's just no other group of stocks that rally like biotechs. As we've said in DailyWealth before, if you catch just one biotech bull market, you'll never have to work again... The last major biotech bull market topped in 2000, along with technology stocks. They've been dogs since then. On March 6, 2000, the Nasdaq Biotech Index was around 1,600. Today, it's around 800 – still down 50% from its peak more than[More...]

Carnegie Mellon exhibit blurs line between artist, tools

Fri, 06 Nov 2009 03:52:00 GMT

Nov. 5--Art that whispers, learns and evolves is on display at Carnegie Mellon University's recently opened Gates Center for Computer Science.
The class was jointly taught last spring by Carlos Guestrin, an associate professor of computer science and machine learning at Carnegie Mellon's School of Computer Science, and Osman Khan, a visiting associate professor of art in the College of Fine Arts.
The seventh work, "Generation 243," was created by Scott Draves, a software artist who received his doctorate in 1997 from the computer science department.

: iStockAnalyst.com Symbols Feed

FDA Calendar Extreme Trades: 85 Single Digit Stocks

Dendreon (DNDN) Rises As New Board Members Are Appointed

The Next Big Thing In Health Care: How To Profit From Immunotherapy & Regenerative Medicine

SurModics, Inc. (SRDX) Signs Agreement With Genentech and Roche

BioMed News Bytes: Dendreon, Chelsea, Cytori, Cephalon, OraSure, Genzyme, Lixte

BioMed News Bytes: BSD Medical, Provectus, Incyte, OncoMethylome

Pressure BioSciences (NASDAQ: PBIO): A New Paradigm For Sample Processing

Emerging Market Or Pharma

Spotlight On: Biotech

Catch These Stocks And You'll Never Have To Work Again

Carnegie Mellon exhibit blurs line between artist, tools

The News and Advance, Lynchburg, Va., Darrell Laurant Column: A Problem That Needs to Be Addressed

Catch Up on Tribune Watchdog Reporting: 10 Reports That Got Results

MandT Reports 41% Increase in Profits for Third Quarter

MandTreports 41% Increase in Profits for Third Quarter

Novato Study Shows Downtown Business Mix Short on Retail

Roche Deal Lifts SurModics Stock: Eden Prairie Firm Could Take in $200M

OPINION: Rebuilding Las Vegas

EDITORIAL: Letters: Hinkle Column Marginalized Minorities

Utilities' Smart Meters Save Money, but Erode Privacy

Genentech Announces Voluntary Withdrawal of Raptiva from the U.S. Market

FDA Advisory Committee Unanimously Recommends Accelerated Approval of Avastin for Previously Treated Brain Cancer (Glioblastoma)

Roche Completes Acquisition of Genentech

Roche Completes Tender Offer for Genentech

Zacks Analyst Blog Highlights: Vivo Participacoes, America Movil, TIM Participacoes, Amylin Pharmaceuticals, Inc. And Eli Lilly.

Capacity Crowd at 2009 Southeast Venture Conference Optimistic About Market - Mar 19 2009 6:53PM

Capacity Crowd at 2009 Southeast Venture Conference Optimistic About Market - Mar 19 2009 2:52PM

OSI Pharmaceuticals Submits Supplemental New Drug Application to the FDA for Tarceva as a First-Line Maintenance Therapy in Advanced Non-Small Cell Lung Cancer

Zacks Industry Outlook Highlights: Roche, Genentech, Gilead Sciences and CV Therapeutics

Over 80 Life Science Industry Exhibitors at the NYBA Annual Meeting

Form 4 Yang Patrick Y For: Mar 26 (10K)

Form 4 Andreatta Robert E For: Mar 26 (10K)

Form 4 CLARK IAN T For: Mar 26 (10K)

Form 4 GENENTECH INC For: Mar 26 Filed by: SANDERS CHARLES A (10K)

Form 4 BOYER HERBERT W PH D For: Mar 26 (10K)

Form 4 REED DEBRA L For: Mar 26 (10K)

Form 4 EBERSMAN DAVID A For: Mar 26 (10K)

Form 4 LEVINSON ARTHUR D For: Mar 26 (10K)

Form 4 DESMOND HELLMANN SUSAN For: Mar 26 (10K)

Form 4 SCHELLER RICHARD H For: Mar 26 (10K)